SpyGlass Pharma公司宣布,其创新性Bim-Iol系统在为期12个月的I/II期临床试验中取得了积极的顶线结果。该数据展现了该系统在眼科治疗领域的应用潜力。
SpyGlass Pharma公司宣布,其创新性Bim-Iol系统在为期12个月的I/II期临床试验中取得了积极的顶线结果。该数据展现了该系统在眼科治疗领域的应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.